ES2095566T3 - Suspension farmaceutica acuosa para agentes activos farmaceuticos. - Google Patents

Suspension farmaceutica acuosa para agentes activos farmaceuticos.

Info

Publication number
ES2095566T3
ES2095566T3 ES93301018T ES93301018T ES2095566T3 ES 2095566 T3 ES2095566 T3 ES 2095566T3 ES 93301018 T ES93301018 T ES 93301018T ES 93301018 T ES93301018 T ES 93301018T ES 2095566 T3 ES2095566 T3 ES 2095566T3
Authority
ES
Spain
Prior art keywords
suspension
aqueous
pharmaceutical
aqueous pharmaceutical
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93301018T
Other languages
English (en)
Inventor
Cynthia M Blase
Manoj N Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Application granted granted Critical
Publication of ES2095566T3 publication Critical patent/ES2095566T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION DE SUSPENSION FARMACEUTICA ACUOSA QUE COMPRENDE: DESDE APROX. 0,2 % HASTA 20 % DE UN PRINCIPIO ACTIVO FARMACEUTICO SOLUBLE SUSTANCIALMENTE EN AGUA, POR EJEMPLO, ACETAMINOFENO; UNA CANTIDAD DE GOMA XANTANO Y CELULOSA MICROCRISTALINA EFICAZ EN LA ESTABILIZACION DE LA SUSPENSION; UNA CANTIDAD EFECTIVA DE COMPOSICIONES PARA ENMASCARAR EL SABOR, Y AGUA, ASI COMO UN PROCESO PARA PRODUCIR DICHAS SUSPENSIONES FARMACEUTICAS ACUOSAS.
ES93301018T 1992-02-14 1993-02-12 Suspension farmaceutica acuosa para agentes activos farmaceuticos. Expired - Lifetime ES2095566T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/835,877 US5272137A (en) 1992-02-14 1992-02-14 Aqueous pharmaceutical suspension for pharmaceutical actives

Publications (1)

Publication Number Publication Date
ES2095566T3 true ES2095566T3 (es) 1997-02-16

Family

ID=25270689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93301018T Expired - Lifetime ES2095566T3 (es) 1992-02-14 1993-02-12 Suspension farmaceutica acuosa para agentes activos farmaceuticos.

Country Status (5)

Country Link
US (2) US5272137A (es)
EP (1) EP0556057B1 (es)
AU (1) AU671610B2 (es)
CA (1) CA2089430C (es)
ES (1) ES2095566T3 (es)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
CA2121435C (en) * 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
WO1995000133A1 (en) * 1993-06-25 1995-01-05 Ibah, Inc. Taste-masked acetaminophen suspensions and methods of making the same
US5455050A (en) * 1993-11-12 1995-10-03 Mcneil-Ppc, Inc. Aqueous antacids with calcium carbonate and magnesium salt
US5534552A (en) * 1994-03-02 1996-07-09 Warner-Lambert Company Clear non-alcoholic sinus and allergy medication
WO1996003976A1 (en) * 1994-08-01 1996-02-15 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5637313A (en) * 1994-12-16 1997-06-10 Watson Laboratories, Inc. Chewable dosage forms
US5563177A (en) * 1995-01-30 1996-10-08 American Home Products Corporation Taste masking guaifenesin containing liquids
DE69632257T2 (de) * 1995-07-14 2005-04-28 Eli Lilly & Co. (Nz) Ltd., Manukau Formulierungen mit monensin
AU774516C (en) * 1995-07-14 2005-12-22 Eli Lilly & Co (Nz) Limited Ionophore antibiotic formulations
NZ272574A (en) * 1995-07-14 1999-02-25 Lilly Eli & Co Nz Ltd Aqueous base suspension concentrate containing at least one ionophore antibiotic and wetting agent and/or a surfactant and xanthan gum optionally with a suspension agent, an antifreeze agent and an antifoaming agent; drench for veterinary treatment
DE19529862A1 (de) * 1995-08-14 1997-02-20 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
NZ280384A (en) 1995-11-02 1997-01-29 Lilly Eli & Co Nz Ltd Animal feed supplement comprising a wettable powder composition of an ionophore antibiotic
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
FR2751875B1 (fr) * 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
WO1999045937A1 (en) * 1998-03-11 1999-09-16 Smithkline Beecham Corporation Process of making an aqueous calcium carbonate suspension
EP1079808B1 (en) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
EP1109461B1 (en) * 1998-07-07 2004-10-06 McNEIL-PPC, INC. Method of improving sweetness delivery of sucralose
JP4540231B2 (ja) 1998-10-28 2010-09-08 三栄源エフ・エフ・アイ株式会社 スクラロースを含有する組成物及びその応用
US20110189348A1 (en) * 1998-10-28 2011-08-04 San-Ei Gen F.F.I., Inc. Compositions containing sucralose and application thereof
USH2044H1 (en) 1998-11-02 2002-09-03 Mcneil-Ppc, Inc. Container with retaining member
WO2000030616A1 (en) 1998-11-20 2000-06-02 Rtp Pharma Inc. Dispersible phospholipid stabilized microparticles
DE60017881T2 (de) 1999-04-06 2006-04-13 Ethypharm Trinkbare pharmazeutische suspension von ibuprofen
TW592725B (en) * 1999-10-26 2004-06-21 Janssen Pharmaceutica Nv Galantamine oral solution
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6787164B2 (en) 2000-02-23 2004-09-07 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US6759062B2 (en) 2000-02-23 2004-07-06 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US6793942B2 (en) 2000-02-23 2004-09-21 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US6841544B2 (en) * 2000-02-23 2005-01-11 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US6682761B2 (en) 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
ES2325057T3 (es) 2000-08-31 2009-08-25 Jagotec Ag Particulas molturadas.
AU2002220248A1 (en) 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US7062312B2 (en) * 2001-01-17 2006-06-13 Pediamed Pharmaceuticals, Inc. Combination and method including a visual marker for determining compliance with a medication regimen
BR0207930A (pt) * 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Composições farmacêuticas lìquidas com sabor mascarado
US20020193342A1 (en) * 2001-05-09 2002-12-19 Hamman John P. Modifying undesirable tastes
NZ530889A (en) * 2001-07-31 2005-03-24 Wyeth Corp Use of sucralose as a sweetening agent combined with pH modulation of chemical formulations generates enhanced taste-masking effects
US20030039687A1 (en) * 2001-08-01 2003-02-27 Michael Corbo Taste masking composition
KR20030047503A (ko) * 2001-12-11 2003-06-18 진양제약주식회사 소브레롤·아세트아미노펜 복합 건조시럽제 및 액제
GB2398005B (en) * 2002-02-20 2005-09-14 Strides Arcolab Ltd Orally administrable pharmaceutical formulation
US6926906B2 (en) * 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
US6602490B1 (en) * 2002-03-04 2003-08-05 Richard A. Cloonan Dental cleaning formulation and manufacturing process
US6998480B2 (en) 2002-03-08 2006-02-14 Tate & Lyle Public Limited Company Process for improving sucralose purity and yield
US7049435B2 (en) 2002-03-08 2006-05-23 Tate & Lyle Public Limited Company Extractive methods for purifying sucralose
JP4619658B2 (ja) * 2002-03-12 2011-01-26 富山化学工業株式会社 快い味の経口懸濁液および方法
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US7906145B2 (en) * 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US7462232B2 (en) 2002-05-14 2008-12-09 Fmc Corporation Microcrystalline cellulose compositions
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
US20060088638A1 (en) * 2002-07-29 2006-04-27 Merkel Carolyn M Method of improving sweetness delivery of sucralose
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040185032A1 (en) * 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US7522955B2 (en) * 2003-10-03 2009-04-21 Michael Rontal Method and apparatus for the ultrasonic cleaning of biofilm coated surfaces
DK1523984T3 (da) * 2003-10-13 2007-03-26 Zoser B Salama Farmaceutisk sammensætning indeholdende oxoplatin og dettes salte
US20050095300A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
BRPI0509103A (pt) * 2004-04-05 2007-08-28 Fmc Corp estabilizantes de mcc/hidrocolóide e composições comestìveis compreendendo os mesmos
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) * 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060093631A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060093630A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
DK1824493T3 (da) * 2004-12-06 2008-12-08 Janssen Pharmaceutica Nv Oral suspension, der omfatter meloxicam
GB0507167D0 (en) * 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
US7314893B2 (en) * 2005-06-06 2008-01-01 Arkema Inc. Acrylic copolymers with improved low temperature performance
US7879382B2 (en) * 2005-09-30 2011-02-01 Fmc Corporation Stabilizers and compositions and products comprising same
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
BRPI0709606B8 (pt) 2006-03-16 2021-05-25 Tris Pharma Inc suspensão líquida administrável oralmente com características de liberação modificada
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
GB2438287A (en) 2006-05-19 2007-11-21 Norbrook Lab Ltd Stable aqueous suspension
US20080014275A1 (en) * 2006-07-13 2008-01-17 Buehler Gail K Pharmaceutical suspensions and related methods
US8932629B2 (en) * 2006-10-27 2015-01-13 Fmc Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
US8394415B2 (en) 2006-11-21 2013-03-12 Mcneil-Ppc, Inc Modified release analgesic suspensions
EP2126574B1 (en) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090137645A1 (en) * 2007-10-31 2009-05-28 Midlothian Laboratories, Llc Shelf-Stable Famotidine Granulates for Oral Suspensions
US8436156B2 (en) * 2008-01-04 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
WO2009117317A1 (en) * 2008-03-20 2009-09-24 Tate & Lyle Technology Ltd Removal of acids from tertiary amide solvents
US8436157B2 (en) * 2008-03-26 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
WO2009124113A1 (en) * 2008-04-03 2009-10-08 Tate & Lyle Technology Ltd. Extraction of less polar impurities from sucralose containing aqueous feed streams
US20090299055A1 (en) * 2008-04-03 2009-12-03 Tate & Lyle Technology Limited Purification of Sucralose Containing Feed Streams for Sucralose Crystallization
WO2009137193A2 (en) * 2008-04-03 2009-11-12 Tate & Lyte Technology Ltd Effect of carbohydrate concentration on sucralose extraction efficiency
US8497367B2 (en) * 2008-04-03 2013-07-30 Tate & Lyle Technology Limited Sucralose purification process
AR071134A1 (es) * 2008-04-03 2010-05-26 Tate & Lyle Technology Ltd Cristalizacion de sucralosa a partir de chorros que contienen sucralosa
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
GB2469158B (en) 2009-03-31 2011-09-28 Peter J Seaberg Base-assisted formation of tin-sucrose adducts
GB2474311B (en) * 2009-10-12 2012-10-17 Tate & Lyle Technology Ltd Low temperature, single solvent process for the production of sucrose-6-ester
GB2474310B (en) 2009-10-12 2012-02-29 Tate & Lyle Technology Ltd Process for the production of sucrose-6-ester
US20120027876A1 (en) * 2010-07-27 2012-02-02 Sara Beth Ford Composition and Method for the Topical Treatment of Dermatitis
US8518438B2 (en) 2011-01-14 2013-08-27 Enspire Group, Llc Highly concentrated liquid acetaminophen solutions
JP5778567B2 (ja) * 2011-01-24 2015-09-16 富士フイルム株式会社 経口用組成物
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
GB201110520D0 (en) 2011-05-10 2011-08-03 Tate & Lyle Technology Ltd Extraction of carboxylic acids with tin compounds
WO2013052118A1 (en) 2011-10-05 2013-04-11 Fmc Corporation Stabilizer composition of co-attrited microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
JP6188030B2 (ja) 2011-10-05 2017-08-30 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 微結晶セルロースおよびカルボキシメチルセルロースの安定化剤組成物、該組成物の製造方法並びに食品製品
PL2787837T3 (pl) 2011-12-09 2017-09-29 Fmc Corporation Współścierana kompozycja stabilizatora
US8969416B2 (en) 2012-03-29 2015-03-03 Enspire Group LLC Polyvinylpyrrolidone-containing acetaminophen liquid formulations
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
TR201618030T2 (tr) 2014-08-14 2018-09-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Tadı düzeltilmiş parasetamol formülasyonları.
RU2607965C1 (ru) * 2015-08-26 2017-01-11 Общество с ограниченной ответственностью "Трейдсервис" Жидкая лекарственная форма фенспирида и способ ее получения
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
CN106606476A (zh) * 2015-10-27 2017-05-03 康芝药业股份有限公司 一种布洛芬混悬滴剂及其制备方法
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108721325B (zh) * 2017-04-13 2020-03-06 辽宁大熊制药有限公司 蒙脱石混悬液及其制备方法
CN108721213A (zh) * 2017-04-13 2018-11-02 辽宁大熊制药有限公司 铝镁混悬液及其制备方法
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US20210290532A1 (en) 2017-11-02 2021-09-23 Max Spielberg Pharmaceutical syrup formulation or suspension
EP3836899A2 (en) * 2018-08-18 2021-06-23 FTF Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
EP3836898A2 (en) 2018-08-18 2021-06-23 FTF Pharma Private Limited Pharmaceutical suspension for oral dosage
AU2019328411B2 (en) 2018-08-28 2022-02-10 Gsk Consumer Healthcare Sarl Paracetamol liquid suspensions
CN112274483A (zh) * 2020-10-28 2021-01-29 河北冀衡药业股份有限公司 一种对乙酰氨基酚混悬滴剂及其制备方法
CN114028331B (zh) * 2021-11-03 2022-11-18 北京鑫开元医药科技有限公司 镁加铝混悬液及其制备工艺
CN116270457A (zh) * 2023-03-22 2023-06-23 浙江贝灵生物医药有限公司 一种用于药物临配的混合型液体药用辅料及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539365A (en) * 1967-02-13 1970-11-10 Fmc Corp Dispersing and stabilizing agent comprising beta-1,4 glucan and cmc and method for its preparation
US4145440A (en) * 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
US4198390A (en) * 1979-01-31 1980-04-15 Rider Joseph A Simethicone antacid tablet
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
US4327076A (en) * 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4923981A (en) * 1982-09-03 1990-05-08 Sbp, Inc. Use of parenchymal cell cellulose to improve comestibles
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US5173305A (en) * 1985-03-06 1992-12-22 Grimberg Georges Serge Composition for protection of oesogastroduodenal mucous membrane
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
US4857324A (en) * 1985-10-08 1989-08-15 American Home Products Corporation (Del.) Exogenously acidified antacid compositions having cytoprotective properties
US4716033A (en) * 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
US4711774A (en) * 1986-03-27 1987-12-08 Warner-Lambert Company Medicament adsorbates with complex magnesium aluminum silicate and their preparation
US4717565A (en) * 1986-03-27 1988-01-05 Warner-Lambert Company Process for the preparation of medicament adsorbates
US4761274A (en) * 1986-03-27 1988-08-02 Warner-Lambert Company Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
US4895723A (en) * 1986-09-08 1990-01-23 Amer And Company Cholestyramine compositions and method for preparation thereof
CA1287627C (en) * 1986-11-21 1991-08-13 Arthur P.G. Wright Essentially pure polyalcohol aluminum complexes and their preparation
CA1276022C (en) * 1986-11-21 1990-11-06 Arthur P. G. Wright Essentially pure acidic amine ligand aluminum complexes and their preparation
US4882324A (en) * 1986-11-21 1989-11-21 Wright Arthur P G Essentially pure acid hydroxyl ligand aluminum complexes and their preparation
US4772724A (en) * 1986-12-02 1988-09-20 Warner-Lambert Canada Inc. Essentially pure acid hydroxyl ligand aluminum complexes and their preparation
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5013557A (en) * 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
US5196436A (en) * 1990-10-31 1993-03-23 The Procter & Gamble Company Dextromethorphan antitussive compositions
US5107842A (en) * 1991-02-22 1992-04-28 Molecular Biosystems, Inc. Method of ultrasound imaging of the gastrointestinal tract
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same

Also Published As

Publication number Publication date
CA2089430C (en) 1998-04-21
US5409907A (en) 1995-04-25
AU671610B2 (en) 1996-09-05
EP0556057A1 (en) 1993-08-18
AU3292493A (en) 1993-08-19
US5272137A (en) 1993-12-21
EP0556057B1 (en) 1996-10-09
CA2089430A1 (en) 1993-08-15

Similar Documents

Publication Publication Date Title
ES2095566T3 (es) Suspension farmaceutica acuosa para agentes activos farmaceuticos.
AR010288A1 (es) Composicion micobactericida concentrada acuosa; composicion desinfectante de superficies duras y metodo de desinfeccion de una superficie dura
ES2178263T3 (es) Composiciones oftarmologicas que contienen un glicosido cationico y unagente terapeutico anionico.
GT199900199A (es) Composiciones de glisofato acuoso altamente concentrado.
DE69011766T2 (de) Wässerige Arzneisuspension für im wesentlichen wasserunlösliche Arzneiwirkstoffe.
HUP0302021A2 (hu) Szteroid tartalmú stabilizált vizes szuszpenziók parenterális használathoz
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
IL114193A0 (en) Ophthalmic pharmaceutical compositions
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
ATE234634T1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
AR026189A1 (es) Material activo contenido dentro de microesferas de hidrogel
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
KR100260061B1 (en) Vitamin e drop
BR9604942A (pt) Método e composição para melhorar a qualidade da grama
ES2152016T3 (es) Solucion oftalmica de pranoprofeno conteniendo amina organica.
CA2377024A1 (en) Ophthalmic composition comprising ketotifen
ECSP034915A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
DE69805860D1 (de) Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
ES2052530T3 (es) Composiciones farmaceuticas liofilizadas de acidos carboxilicos de fenilquinolina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 556057

Country of ref document: ES